Illumina's TruSight Next-Generation Sequencing Assay Receives FDA Breakthrough Device Designation

Illumina's TruSight Oncology 500 next-generation sequencing assay has been assigned a breakthrough device status by the FDA.

from Latest articles from Cancer Therapy Advisor News http://bit.ly/2T9Qg6G